Functional imaging with 18F-FDG PET/CT and diffusion weighted imaging (DWI) in early response evaluation of combination therapy of elotuzumab, lenalidomide, and dexamethasone in a relapsed multiple myeloma patient
Elotuzumab is the first monoclonal antibody approved for the treatment of relapsed-refractory multiple myeloma (MM) in combination with lenalidomide, an immunodulatory drug, and dexamethasone. We report on a multiply pre-treated MM patient with disease progression due to appearance of new focal lesi...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 December 2017
|
| In: |
Diagnostics
Year: 2017, Jahrgang: 7, Heft: 4 |
| ISSN: | 2075-4418 |
| DOI: | 10.3390/diagnostics7040061 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.3390/diagnostics7040061 Verlag, kostenfrei, Volltext: http://www.mdpi.com/2075-4418/7/4/61 
|
| Verfasserangaben: | Christos Sachpekidis, Antonia Dimitrakopoulou-Strauss, Stefan Delorme and Hartmut Goldschmidt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576022420 | ||
| 003 | DE-627 | ||
| 005 | 20230427042924.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180605s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/diagnostics7040061 |2 doi | |
| 035 | |a (DE-627)1576022420 | ||
| 035 | |a (DE-576)506022420 | ||
| 035 | |a (DE-599)BSZ506022420 | ||
| 035 | |a (OCoLC)1341010834 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sachpekidis, Christos |d 1983- |e VerfasserIn |0 (DE-588)1099707269 |0 (DE-627)858738651 |0 (DE-576)469338482 |4 aut | |
| 245 | 1 | 0 | |a Functional imaging with 18F-FDG PET/CT and diffusion weighted imaging (DWI) in early response evaluation of combination therapy of elotuzumab, lenalidomide, and dexamethasone in a relapsed multiple myeloma patient |c Christos Sachpekidis, Antonia Dimitrakopoulou-Strauss, Stefan Delorme and Hartmut Goldschmidt |
| 264 | 1 | |c 15 December 2017 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Die Zahl 18 ist in der Vorlage hochgestellt | ||
| 500 | |a Gesehen am 05.06.2018 | ||
| 520 | |a Elotuzumab is the first monoclonal antibody approved for the treatment of relapsed-refractory multiple myeloma (MM) in combination with lenalidomide, an immunodulatory drug, and dexamethasone. We report on a multiply pre-treated MM patient with disease progression due to appearance of new focal lesions on imaging modalities, who was started on a combination treatment of elotuzumab, lenalidomide, and dexamethasone. After completion of three cycles of the new therapy the patient responded very well with a major decline of serological myeloma activity parameters serum monoclonal protein, kappa light chains, free light chains (FLC) ratio. The patient was also monitored with the functional imaging modalities 18F-FDG PET/CT and diffusion weighted imaging (DWI), which exhibited a mismatch of almost complete metabolic remission on positron emission tomography/computed tomography (PET/CT) with 18F-fluoro-2-deoxy-d-glucose (18F-FDG) (consistent with the serological response), and signal elevation persistence on DWI. This case demonstrates the potentially superior performance of 18F-FDG PET/CT over DWI in early response evaluation of combined treatment with a monoclonal antibody, an immunomodulatory drug, and dexamethasone in MM. | ||
| 650 | 4 | |a diffusion weighted imaging (DWI) | |
| 650 | 4 | |a elotuzumab | |
| 650 | 4 | |a lenalidomide | |
| 650 | 4 | |a multiple myeloma | |
| 700 | 1 | |a Dimitrakopoulou-Strauss, Antonia |d 1963- |e VerfasserIn |0 (DE-588)1076688373 |0 (DE-627)835256901 |0 (DE-576)167486055 |4 aut | |
| 700 | 1 | |a Delorme, Stefan |e VerfasserIn |0 (DE-588)105842808X |0 (DE-627)796879761 |0 (DE-576)179470140 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnostics |d Basel : MDPI, 2011 |g 7 (2017,4) Artikel-Nummer 61, 5 Seiten |h Online-Ressource |w (DE-627)718627814 |w (DE-600)2662336-5 |w (DE-576)365413917 |x 2075-4418 |7 nnas |a Functional imaging with 18F-FDG PET/CT and diffusion weighted imaging (DWI) in early response evaluation of combination therapy of elotuzumab, lenalidomide, and dexamethasone in a relapsed multiple myeloma patient |
| 773 | 1 | 8 | |g volume:7 |g year:2017 |g number:4 |g extent:5 |a Functional imaging with 18F-FDG PET/CT and diffusion weighted imaging (DWI) in early response evaluation of combination therapy of elotuzumab, lenalidomide, and dexamethasone in a relapsed multiple myeloma patient |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/diagnostics7040061 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://www.mdpi.com/2075-4418/7/4/61 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180605 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 4 |y j | ||
| 998 | |g 1076688373 |a Dimitrakopoulou-Strauss, Antonia |m 1076688373:Dimitrakopoulou-Strauss, Antonia |d 910000 |e 910000PD1076688373 |k 0/910000/ |p 2 | ||
| 998 | |g 1099707269 |a Sachpekidis, Christos |m 1099707269:Sachpekidis, Christos |d 910000 |d 910100 |e 910000PS1099707269 |e 910100PS1099707269 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1576022420 |e 3011634173 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"15 December 2017"}],"note":["Die Zahl 18 ist in der Vorlage hochgestellt","Gesehen am 05.06.2018"],"title":[{"title":"Functional imaging with 18F-FDG PET/CT and diffusion weighted imaging (DWI) in early response evaluation of combination therapy of elotuzumab, lenalidomide, and dexamethasone in a relapsed multiple myeloma patient","title_sort":"Functional imaging with 18F-FDG PET/CT and diffusion weighted imaging (DWI) in early response evaluation of combination therapy of elotuzumab, lenalidomide, and dexamethasone in a relapsed multiple myeloma patient"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1576022420","relHost":[{"part":{"volume":"7","extent":"5","text":"7 (2017,4) Artikel-Nummer 61, 5 Seiten","issue":"4","year":"2017"},"language":["eng"],"disp":"Functional imaging with 18F-FDG PET/CT and diffusion weighted imaging (DWI) in early response evaluation of combination therapy of elotuzumab, lenalidomide, and dexamethasone in a relapsed multiple myeloma patientDiagnostics","type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisherPlace":"Basel","dateIssuedKey":"2011","publisher":"MDPI","dateIssuedDisp":"2011-"}],"note":["Gesehen am 28.05.2020"],"pubHistory":["1.2011 -"],"title":[{"title":"Diagnostics","title_sort":"Diagnostics","subtitle":"open access journal"}],"id":{"issn":["2075-4418"],"zdb":["2662336-5"],"eki":["718627814"]},"recId":"718627814","physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["Christos Sachpekidis, Antonia Dimitrakopoulou-Strauss, Stefan Delorme and Hartmut Goldschmidt"]},"physDesc":[{"extent":"5 S."}],"id":{"doi":["10.3390/diagnostics7040061"],"eki":["1576022420"]},"person":[{"display":"Sachpekidis, Christos","family":"Sachpekidis","given":"Christos","role":"aut"},{"role":"aut","given":"Antonia","display":"Dimitrakopoulou-Strauss, Antonia","family":"Dimitrakopoulou-Strauss"},{"family":"Delorme","display":"Delorme, Stefan","given":"Stefan","role":"aut"},{"given":"Hartmut","role":"aut","family":"Goldschmidt","display":"Goldschmidt, Hartmut"}],"language":["eng"]} | ||
| SRT | |a SACHPEKIDIFUNCTIONAL1520 | ||